CHICAGO, May 16, 2023 (GLOBE NEWSWIRE) -- Data Bridge Market Research has just released its extensive report on the "Headache Disorders Market" which details the industry's past, present, and future in terms of both products and marketing. They also detail current and projected market trends, sales and distribution channels, and economic developments. A better-quality and comprehensive market research report endows professionals with a lot of aspects about the market and the industry. The winning Headache Disorders report presents the market potential for each geographical region based on the growth rate, macroeconomic parameters, consumer buying patterns, preferences for particular products,s and market demand and supply scenarios. Market segmentation analyses the usage of the product with respect to its applications, end user or with respect to geography. Businesses can attain unparalleled and comprehensive insights along with the best acquaintance of emerging market opportunities with the Headache Disorders market research report.
By thinking from the customer's point of view, a team of researchers, analysts, and industry experts work carefully to generate Headache Disorders market report. This global market research report studies the market at regional and global levels by considering major geographical areas. Besides, this market research report makes clients aware of the various strategies that are used by key players of the market. To succeed in this promptly changing marketplace, businesses must take up the market research report solution such as the Headache Disorders market research report. The market data and information included in this report not only aid businesses make data-driven decisions but also assure maximum return on investment (ROI).
Data Bridge Market Research analyses a growth rate in the headache disorders market in the forecast period 2023-2030. The expected CAGR of the headache disorders market tends to be around 6.4% in the mentioned forecast period. The market was valued at USD 3.99 billion in 2022, and it would grow up to USD 6.55 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Download a PDF Sample of the Headache Disorders Market @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-headache-disorders-market
Headache disorders is the most widespread nervous system disorders which are typically characterized by consistent headaches. Headache is an extreme and disabling symptom of a few major headache disorders, which includes migraine, cluster headache, tension-type headache and others. Another incident cause of headaches is overuse of medication. Antipsychotic medications, antiseizure medications, calcium channel blockers, antidepressants, and nonsteroidal anti-inflammatory drugs (NSAIDs) are the numerous drugs used in the treatment of headache disorders.
It is projected that over half of the adult population has witnessed a headache at least once in the previous year. Recurring headache disorders are associated with personal and societal costs of pain, disability, reduced quality of life, and financial cost. Only a small proportion of people having headache issues are diagnosed appropriately by physicians. Headache is underappreciated, under-diagnosed, and under-treated worldwide. Most of the currently approved drugs assign for the acute form of the condition, which is further led by generic triptans as the first-line treatment.
Recent Development
- In 2021, FDA had approved the first and only oral CGRP receptor antagonist called QULIPTA™, which is particularly developed for the preventive treatment of migraine. CGRP and its receptors are used for nervous system that is related with migraine pathogenesis, and CGRP levels have been found to be more during migraine attacks in studies. QULIPTA is a once-daily medication that blocks CGRP. It comes in three different dosage forms including 10 mg, 30 mg, and 60 mg.
Key Growth Drivers:
- Rising Cases of Depression
The increasing number of cases of depression is a primary factor boosting the headache disorders market's growth rate during the forecast period of 2023-2030. Unhealthy lifestyle of people such as high alcohol consumption, severe changes in eating or sleeping pattern are the major risk factors which is expanding the frequency of depression and further causing headache. Additionally, emotional stress associated with family and friends, school or work is anticipated to boost the market’s growth rate during the forecast period.
- Increased Healthcare Expenditure
A major factor prompting the growth rate of headache disorders market is the increasing healthcare expenditure that helps in improving its improved infrastructure. Moreover, numerous government organizations aims to improve the healthcare infrastructure by growing funding and this will in turn influence the market dynamics. Thus, it boost the market growth.
The Headache Disorders Market is Dominated by Firms Such as
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Merck & Co., Inc. (U.S.)
- Abbvie, Inc (Ireland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Hikma Pharmaceuticals PLC (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Bayer AG (Germany)
- Boehringer Ingelheim International GmbH. (Germany)
- Dr. Reddy’s Laboratories Ltd. (India)
- Gilead Sciences, Inc. (U.S.)
- Amgen Inc. (U.S.)
- Lilly (U.S.)
Download the Complete Research Study Here in PDF Format @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-headache-disorders-market
The following is a versatile analysis of all the prominent reader queries addressed in the report. Based on these unique references, market players looking out for seamless market penetration can well design and implement high revenue generation business strategies.
- The report highlights the market size and dimensions along with growth rate references feasible through the forecast span
- Key market growth initiators and factors influencing the growth
- Prominent vendors, stakeholders as well as their growth favoring business activities
- Crucial trend analysis and Porter's five forces description
- Novel growth opportunities and avenues steering systematic growth decisions in the global Headache Disorders market
Opportunities for Key Players:
- Increasing Demand for Preventive Treatment
Preventive or prophylactic treatment which includes the prescription of off-label and generic medications named beta-blockers such as atenolol and propranolol, anti-epileptics such as topiramate, and divalproex sodium. Presently, Allergan’s Botox, Amgen/ Novartis’s Aimovig, and Teva’s Ajovy (CGRP mAb) are the only drugs that are approved for migraine prevention. Though, Botox requires more than 30 injections across the forehead, shoulders, and neck and does not provide relief from episodic migraine.
- Increased R&D Activities
Ongoing research focuses on using novel mechanisms of action such as corticotrophin receptor antagonism, CGRP-based receptor and ligand inhibition, and nitrous oxide inhibition. Wide approval of CGRP monoclonal antibodies is one of the major developments in the preventive market. Though numerous companies are anticipated to grow in the next two years, Amgen and Novartis are poised to benefit from Aimovig’s first-mover status, favourable reimbursement scenario, and easy to use the pen-device mode of administration. In May 2018, the drug was launched in North America and in Europe in July 2018 and has observed a positive response from patients and healthcare providers alike.
Key Market Segments Covered in Headache Disorders Industry Research
Type
- Tension-type headache
- Cluster Headache
- Medication-overuse Headache
Diagnosis
- Complete Blood Count
- Skull X-rays
- Sinus X-rays
- CT Scan
- Magnetic resonance imaging (MRI)
Treatment
- Medication
- Heat Therapy
- Diet Changes
- Acupuncture
- Oxygen Therapy
Route of Administration
- Oral
- Parenteral
End-Users
- Hospitals
- Specialty Clinics
- Homecare
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Browse More about Headache Disorders Market Study @ https://www.databridgemarketresearch.com/reports/global-headache-disorders-market
Fundamental Aim of Headache Disorders Market Report
In the Headache Disorders market, every company has goals, but this report focuses in on the most important ones, allowing you to gain insight into the competition, the future of the market, potential new products, and other useful information that can boost your sales significantly.
- Factors influencing the Headache Disorders Market Size and growth rate.
- Major alterations to the Headache Disorders Market in the near future.
- Notable Market rivals around the world.
- The Headache Disorders Market's Future Scope and Product Outlook
- Future-promising emerging markets.
- The Market Presents Difficult Challenges and Threats.
- Sales data and profiles of the world's leading Headache Disorders players
Headache Disorders Market Regional Analysis/Insights:
The major countries covered in the headache disorders market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the market due to the increasing incidence of headache disorders and growing healthcare expenditure. Moreover, increasing focus of major market players on novel technology will enhance the market’s growth rate in this region.
Asia-Pacific is considered to grow in the forecast period because of the increasing number of elderly population in this region. Furthermore, development of healthcare infrastructure and increasing government initiatives will boost the market’s growth rate in this region
This Market Intelligence Report Analyses Some of the Most Crucial Concerns:
- How will the major segments of this international market develop over the next few years?
- Who are the major players that will dominate the market in the future?
- When it comes to this industry, who are the top suppliers and producers?
- How have the most successful companies in the industry planned for future growth and expansion?
- In what sectors might we expect to see the greatest increase in demand over the coming years?
- How many distinct subsets of buyers make up this market?
- Which regional powerhouse do you foresee as becoming the largest player in the international market?
- Does a new coronavirus pandemic have any consequences?
- In what ways are established actors stymied by the entry of newcomers, and how may they be overcome?
Table of Contents:
- Introduction
- Market Segmentation
- Executive Summary
- Premium Insights
- Global Headache Disorders Market: Regulations
- Market Overview
- Global Headache Disorders Market, By Type
- Global Headache Disorders Market, By Diagnosis
- Global Headache Disorders Market, By Treatment
- Global Headache Disorders Market, By Route of Administration
- Global Headache Disorders Market, By End-Users
- Global Headache Disorders Market, By Distribution Channel
- Global Headache Disorders Market, By Region
- Global Headache Disorders Market: Company Landscape
- SWOT Analyses
- Company Profile
- Questionnaires
- Related Reports
Get the Complete Table of Contents @ https://www.databridgemarketresearch.com/toc/?dbmr=global-headache-disorders-market
Explore More Reports:
Cluster Headaches Market, By Drug Type (Triptans, Octreotide, Opioids, Others), Type (Episodic and Chronic), Drug Application (Abortive, Transitional, Preventative), Product Types (Calcium Channel Blockers, Corticosteroids, Sumatriptan, Lithium Carbonate, Ergots, Melatonin, Anti-seizure, Local Anesthetics), End User (Hospitals Clinics, Private Clinics, Retail Pharmacies and Drug Stores, E-commerce), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) https://www.databridgemarketresearch.com/reports/global-cluster-headaches-market
Cluster Headache Drug Market, By Types (Episodic and Chronic), Mechanism of Action (Corticosteroids, Ergot Alkaloids (Dihydroergotamine, Ergotamine), Local Anaesthetics, Calcium Channel Blockers, Triptans, Lithium Carbonate and Anti-Seizures), Drugs Type (Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs), Diagnosis (Neurological Examination, MRI and CT Scan), Treatment (Medication and Surgery), Route of Administration (Oral, Topical, Intravenous and Others), End Users (Hospitals, Homecare, Specialty Clinics and Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-cluster-headache-drug-market
Migraine Drugs Market, By Product Type (Acute Migraine Treatment, Preventive Migraine Treatment), Route of Administration (Oral, Injection, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics and Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-migraine-drugs-market
Migraine Treatment Market, By Types (Episodic, Migraine with Aura, Chronic, and Others), Treatment (Acute/Abortive Treatment, Preventive/Prophylactic Treatment, Non-Pharmacological Therapies and Devices), Route of Administration (Oral, Parenteral, Nasal Sprays, and Others), Product Type (Prescription and Over The Counter), Type (Branded and Generic), End-User (Hospitals, Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies And Others) https://www.databridgemarketresearch.com/reports/global-migraine-treatment-market
North America Migraine Treatment Market, By Types of Migraine (Episodic, Migraine with Aura, Chronic, and Others), Treatment (Acute/Abortive Treatment, Preventive/Prophylactic Treatment, Non-Pharmacological Therapies and Devices), Route of Administration (Oral, Parenteral, Nasal Sprays, and Others), Product Type (Prescription and Over The Counter), Drug Type (Branded and Generic), End User (Hospital and Clinics, Diagnostic Laboratories, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, And Others) https://www.databridgemarketresearch.com/reports/north-america-migraine-treatment-market
Europe Migraine Treatment Market, By Types (Episodic, Migraine with Aura, Chronic and Others), Treatment (Acute/Abortive Treatment, Preventive/Prophylactic Treatment, Non-Pharmacological Therapies and Devices), Route of Administration (Oral, Parenteral, Nasal Sprays, and Others), Product Type (Prescription and Over the Counter), Drug Type (Branded and Generic), End-User (Hospitals, Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others) https://www.databridgemarketresearch.com/reports/europe-migraine-treatment-market
Asia-Pacific Migraine Treatment Market, By Types (Episodic, Migraine with Aura, Chronic and Others), Treatment (Acute/Abortive Treatment, Preventive/ Prophylactic Treatment, Non-Pharmacological Therapies and Devices), Route of Administration (Oral, Parenteral, Nasal Sprays and Others), Product Type (Prescription and Over The Counter), Type (Branded and Generic), End User (Hospitals, Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies And Others) https://www.databridgemarketresearch.com/reports/asia-pacific-migraine-treatment-market
About Data Bridge Market Research:
An absolute way to forecast what the future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the Fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfaction rate.
Contact Us:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- corporatesales@databridgemarketresearch.com
